India, Nov. 20 -- Biological E. Limited (BE), a leading Hyderabad-based vaccine and pharmaceutical company, has announced that the World Health Organisation (WHO) has granted Pre-qualification (PQ) status to their 14-valent Pneumococcal Conjugate Vaccine (PCV), PNEUBEVAX 14(R) (BE-PCV-14).

PNEUBEVAX 14(R) becomes BE's 11th WHO pre-qualified vaccine. Developed specifically to prevent invasive pneumococcal diseases, PNEUBEVAX 14(R) protects against infections caused by 14 different Streptococcus pneumoniae serotypes, including serotypes 22F and 33F-two strains not covered by select other PCVs.

Administered to infants from six weeks of age, PNEUBEVAX 14(R) is designed to guard against serious diseases such as pneumonia, meningitis, and sep...